In situ DC targeting utilizing viral vectors can potentially provide tumor antigens, co-stimulatory, and maturation (i.e., Flt3L) signals (169), enabling DCs to overcome tumor-induced tolerance. This evidence concerns the gene FLT3LG and neoplasm.